Spike Protein News and Research

RSS

New compound may provide a basis for drug development against COVID-19

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, arrived one year ago and turned our lives upside-down.

24 Mar 2021

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

An international team of researchers has found that three commonly used antiviral and antimalarial drugs are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes COVID-19.

24 Mar 2021

Reduced mRNA COVID-19 vaccine response in nursing home residents

A recent study has examined the response of nursing home residents who were naïve to SARS-CoV-2 infection following vaccination by the mRNA BNT162b2 model from Pfizer-BioNTech.

24 Mar 2021

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Researchers at the Division of Infection and Immunity, University College London, UK, have provided key insights into the characteristics of the B.1.1.7 (or UK) variant of SARS-CoV-2.

24 Mar 2021

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

A new study adds to the sum of knowledge about SARS-CoV-2, with respect to its natural and biologically significant mutations, using computational modeling of the virus-receptor interactions. Understanding how viral mutations affect the virus-host interactions is crucial for shaping proper strategies to control the virus.

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

A new study describes the use of a combination of virtual and experimental screening protocols to identify potential inhibitors of the virus, which could lead to rapid drug development.

24 Mar 2021

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

A new preprint study led by Shawn S-C. Li from Western University in Ontario, Canada, provides evidence of epitope-specific antibody responses and designed a test to measure this in relation to disease severity and outcome after infection.

24 Mar 2021

Study reveals arsenal used by protozoans to make leishmaniasis more severe

Researchers have succeeded in revealing the arsenal used by protozoans of the genus Leishmania in human cells to make leishmaniasis more severe, especially in cases of the mucocutaneous variety of the disease, which can cause deformations in patients.

24 Mar 2021

Research suggests toothpaste and mouthwash ingredients could help prevent SARS-CoV-2 infection

Now, new research published on the bioRxiv preprint server focuses on the effect of some typical ingredients present in commercially available mouthwashes and toothpaste on the mechanisms of SARS-CoV-2 entry into host cells.

24 Mar 2021

Glycans play a key role in COVID-19 infection, shows study

A research group at the RIKEN Center for Computational Science (R-CCS) has found that glycans—sugar molecules—play an important role in the structural changes that take place when the virus which causes COVID-19 invades human cells.

24 Mar 2021

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

All viruses mutate as they make copies of themselves to spread and thrive. SARS-CoV-2, the virus the causes COVID-19, is proving to be no different. There are currently more than 4,000 variants of COVID-19, which has already killed more than 2.7 million people worldwide during the pandemic.

23 Mar 2021

Correlation of antibody titers with COVID-19 vaccine efficacy

In a new study the relationship between virus-neutralizing antibody and spike protein-binding IgG antibody levels is explored following vaccination by one of seven currently deployed vaccines. The findings support the use of antibody titers as correlates of protection for COVID-19 vaccines.

23 Mar 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

A new study addresses the issue of passive immunity to SARS-CoV-2 for newborns via breast milk.

23 Mar 2021

Dandelion extract inhibits SARS-CoV-2 in vitro

An exciting new study describes a specific inhibitor of the SARS-CoV-2 found in an extract of the common dandelion that could provide a new and fruitful avenue of drug research.

23 Mar 2021

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimization of fully human antibodies, have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants.

From FairJourney Biologics 23 Mar 2021

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Recently, researchers from the US employed multiple-µs molecular dynamic simulations to compare the relative dynamics, stabilities, and energy differences between the SARS-CoV receptor-binding domain (RBD)-ACE2 and SARS-CoV-2 RBD-ACE2 complexes. The study is published on the preprint server, bioRxiv.

23 Mar 2021

Spike Protein News and Research

New compound may provide a basis for drug development against COVID-19

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

Reduced mRNA COVID-19 vaccine response in nursing home residents

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

Epitope antibody testing is effective in detecting immune responses to SARS-CoV-2

Study reveals arsenal used by protozoans to make leishmaniasis more severe

Research suggests toothpaste and mouthwash ingredients could help prevent SARS-CoV-2 infection

Glycans play a key role in COVID-19 infection, shows study

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

Correlation of antibody titers with COVID-19 vaccine efficacy

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

Study suggests SARS-CoV-2 antibodies in breast milk are robust, neutralizing and durable

Dandelion extract inhibits SARS-CoV-2 in vitro

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News